Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
A Single-Dose, Open-Label, Pharmacokinetic Study Of Ulipristal Acetate In Healthy Subjects With Normal Renal Function And Patients With Moderately Or Severly Impaired Renal Function
Sponsor: Allergan
Listed as NCT02634437, this PHASE1 trial focuses on Renal Function and remains completed. Sponsored by Allergan, it has been updated 8 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Feb 2018 — Mar 2018 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Feb 2017 — Feb 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allergan
For direct contact, visit the study record on ClinicalTrials.gov .